vs
Element Solutions Inc（ESI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Element Solutions Inc的季度营收约是Royalty Pharma plc的1.4倍（$840.0M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 6.7%，领先27.8%），Element Solutions Inc同比增速更快（41.0% vs 4.8%），过去两年Element Solutions Inc的营收复合增速更高（17.1% vs 4.6%）
Element Solutions Inc是一家总部位于美国的特种化学品生产企业，专注于特种化学品领域的生产运营，于纽约证券交易所挂牌上市，业务覆盖全球多个市场，为各行业客户提供专业的特种化学品产品及相关解决方案。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ESI vs RPRX — 直观对比
营收规模更大
ESI
是对方的1.4倍
$622.0M
营收增速更快
ESI
高出36.2%
4.8%
净利率更高
RPRX
高出27.8%
6.7%
两年增速更快
ESI
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $840.0M | $622.0M |
| 净利润 | $56.0M | $214.2M |
| 毛利率 | 38.4% | — |
| 营业利润率 | 13.3% | 62.4% |
| 净利率 | 6.7% | 34.4% |
| 营收同比 | 41.0% | 4.8% |
| 净利润同比 | -43.0% | 2.9% |
| 每股收益（稀释后） | $0.23 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESIRPRX
| Q1 26 | $840.0M | — | ||
| Q4 25 | $676.2M | $622.0M | ||
| Q3 25 | $656.1M | $609.3M | ||
| Q2 25 | $625.2M | $578.7M | ||
| Q1 25 | $593.7M | $568.2M | ||
| Q4 24 | $624.2M | $593.6M | ||
| Q3 24 | $645.0M | $564.7M | ||
| Q2 24 | $612.7M | $537.3M |
净利润ESIRPRX
| Q1 26 | $56.0M | — | ||
| Q4 25 | $6.2M | $214.2M | ||
| Q3 25 | $39.3M | $288.2M | ||
| Q2 25 | $47.4M | $30.2M | ||
| Q1 25 | $98.0M | $238.3M | ||
| Q4 24 | $54.7M | $208.2M | ||
| Q3 24 | $40.3M | $544.0M | ||
| Q2 24 | $93.2M | $102.0M |
毛利率ESIRPRX
| Q1 26 | 38.4% | — | ||
| Q4 25 | 40.9% | — | ||
| Q3 25 | 42.2% | — | ||
| Q2 25 | 42.6% | — | ||
| Q1 25 | 42.2% | — | ||
| Q4 24 | 41.0% | — | ||
| Q3 24 | 41.5% | — | ||
| Q2 24 | 43.6% | — |
营业利润率ESIRPRX
| Q1 26 | 13.3% | — | ||
| Q4 25 | 10.3% | 62.4% | ||
| Q3 25 | 15.4% | 70.1% | ||
| Q2 25 | 15.1% | 36.3% | ||
| Q1 25 | 13.0% | 94.0% | ||
| Q4 24 | 12.0% | 60.9% | ||
| Q3 24 | 14.7% | — | ||
| Q2 24 | 15.7% | 50.2% |
净利率ESIRPRX
| Q1 26 | 6.7% | — | ||
| Q4 25 | 0.9% | 34.4% | ||
| Q3 25 | 6.0% | 47.3% | ||
| Q2 25 | 7.6% | 5.2% | ||
| Q1 25 | 16.5% | 41.9% | ||
| Q4 24 | 8.8% | 35.1% | ||
| Q3 24 | 6.2% | 96.3% | ||
| Q2 24 | 15.2% | 19.0% |
每股收益（稀释后）ESIRPRX
| Q1 26 | $0.23 | — | ||
| Q4 25 | $0.03 | $0.49 | ||
| Q3 25 | $0.16 | $0.67 | ||
| Q2 25 | $0.20 | $0.07 | ||
| Q1 25 | $0.40 | $0.55 | ||
| Q4 24 | $0.22 | $0.46 | ||
| Q3 24 | $0.17 | $1.21 | ||
| Q2 24 | $0.39 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.3M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $2.7B | $9.7B |
| 总资产 | $5.7B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ESIRPRX
| Q1 26 | $177.3M | — | ||
| Q4 25 | $626.5M | $618.7M | ||
| Q3 25 | $594.3M | $938.9M | ||
| Q2 25 | $529.9M | $631.9M | ||
| Q1 25 | $499.2M | $1.1B | ||
| Q4 24 | $359.4M | $929.0M | ||
| Q3 24 | $376.0M | $950.1M | ||
| Q2 24 | $309.3M | $1.8B |
总债务ESIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | $9.0B | ||
| Q3 25 | $1.6B | $8.9B | ||
| Q2 25 | $1.6B | $8.0B | ||
| Q1 25 | $1.6B | $7.6B | ||
| Q4 24 | $1.8B | $7.6B | ||
| Q3 24 | $1.9B | $7.6B | ||
| Q2 24 | $1.9B | $7.6B |
股东权益ESIRPRX
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $9.7B | ||
| Q3 25 | $2.7B | $9.6B | ||
| Q2 25 | $2.6B | $9.5B | ||
| Q1 25 | $2.5B | $9.8B | ||
| Q4 24 | $2.4B | $10.3B | ||
| Q3 24 | $2.4B | $10.3B | ||
| Q2 24 | $2.4B | $9.8B |
总资产ESIRPRX
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.1B | $19.6B | ||
| Q3 25 | $5.0B | $19.3B | ||
| Q2 25 | $5.0B | $18.3B | ||
| Q1 25 | $4.8B | $17.6B | ||
| Q4 24 | $4.9B | $18.2B | ||
| Q3 24 | $5.1B | $18.0B | ||
| Q2 24 | $5.0B | $17.7B |
负债/权益比ESIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | 0.92× | ||
| Q3 25 | 0.61× | 0.93× | ||
| Q2 25 | 0.62× | 0.84× | ||
| Q1 25 | 0.64× | 0.78× | ||
| Q4 24 | 0.76× | 0.74× | ||
| Q3 24 | 0.78× | 0.74× | ||
| Q2 24 | 0.81× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-74.2M | — |
| 自由现金流率自由现金流/营收 | -8.8% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESIRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | $827.1M | ||
| Q3 25 | $100.1M | $702.6M | ||
| Q2 25 | — | $364.0M | ||
| Q1 25 | $26.0M | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | $98.5M | $703.6M | ||
| Q2 24 | — | $658.2M |
自由现金流ESIRPRX
| Q1 26 | $-74.2M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $83.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $85.9M | — | ||
| Q2 24 | — | — |
自由现金流率ESIRPRX
| Q1 26 | -8.8% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 12.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | — | — |
资本支出强度ESIRPRX
| Q1 26 | 3.0% | — | ||
| Q4 25 | 2.5% | — | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.4% | — |
现金转化率ESIRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 3.86× | ||
| Q3 25 | 2.55× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | 0.27× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 2.44× | 1.29× | ||
| Q2 24 | — | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESI
| Electronics ex-Metals | $377.8M | 45% |
| Pass-through Metals | $255.7M | 30% |
| Other | $206.5M | 25% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
